(2S)-2,6-diamino-5,5-dimethylhexanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2,6-diamino-5,5-dimethylhexanoic acid
• 化学式: C₈H₁₈N₂O₂
• 分子量: 174.24
• InChiKey: ZZPUNMWGUXJFJD-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES PEPTIDIQUES ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089894A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：抗体；连接体；以及至少两个活性剂。在优选的实施例中，连接体包括由多个氨基酸组成的肽序列，其中至少两个活性剂通过共价键与氨基酸的侧链连接。抗体药物偶联物可以包括自焚基团，优选地是两个自焚基团。连接体可以包括O-取代的肟，例如，其中肟的氧原子被取代以与活性剂形成共价键连接；肟的碳原子被取代以与抗体形成共价键连接。
• LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE
  申请人：LEGOCHEM BIOSCIENCES, INC.

  公开号：US20220226496A1

  公开（公告）日：2022-07-21

  The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.

  本发明涉及一种配体-药物偶联物，包括一个配体；一个连接剂，通过共价键连接到配体上，具有由特定结构公式表示的三元结构；以及通过共价键连接到连接剂上的活性药物。在配体-药物偶联物中，活性药物由连接剂的三元结构结合，因此可以通过一个连接剂连接更多的活性药物。因此，可以将更多的活性药物输送到靶细胞，每个抗体结合可以输送更多的活性药物，药物和/或毒素可以稳定地到达靶细胞并有效地发挥药效。
• Antibody-drug conjugates comprising branched linkers and methods related thereto
  申请人：LegoChem Biosciences, Inc.

  公开号：US11173214B2

  公开（公告）日：2021-11-16

  The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.

  本发明涉及抗体-药物共轭物（ADC），其中多种活性剂通过至少一种支链连接体与抗体共轭。支链连接体可包括一个支链单元，两种活性剂通过二级连接体与支链单元连接，支链单元通过一级连接体与抗体连接。活性剂可以相同，也可以不同。在某些这样的实施方案中，两个或更多这样的支链连接体被连接到抗体上，例如，2-4 个支链连接体，它们可以分别连接到抗体重链或轻链的不同 C 端半胱氨酸上。支链连接体可包括一个通过第一分支与支链单元偶联的活性剂和一个由聚乙二醇分子组成的与支链单元偶联的第二分支。在某些这样的实施方案中，两个或更多这样的支链连接体被连接到抗体上，例如，2-4 个支链连接体，它们可以分别连接到抗体重链或轻链的不同 C 端半胱氨酸上。
• Conjugates comprising peptide groups and methods related thereto
  申请人：LegoChem Biosciences, Inc.

  公开号：US11167040B2

  公开（公告）日：2021-11-09

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体-药物共轭物，包括抗体、连接体和至少两种活性剂。在优选的实施方案中，连接体包括由多个氨基酸组成的肽序列，至少两种活性剂与氨基酸侧链共价偶联。抗体-药物共轭物可包括一个自巯基，最好是两个自巯基。连接体可包括 O-取代的肟，例如，其中肟的氧原子被一个能将肟与活性剂共价连接的基团取代；肟的碳原子被一个能将肟与抗体共价连接的基团取代。
• CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO
  申请人：LegoChem Biosciences, Inc.

  公开号：EP3380125A1

  公开（公告）日：2018-10-03